[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AdventHealth\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":531},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,45,76,106,127,151,172,193,229,255,276,304,338,373,393,411,433,458,483,509],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100630294","phase-4-methadone-in-the-management-of-post-operative-pain-in-total-knee-replacement-100630294",false,"NCT07485803","Methadone in the Management of Post-Operative Pain in Total Knee Replacement","A Prospective, Randomized Trial Utilizing Methadone in the Management of Post-Operative Pain in Total Knee Replacement","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent from\n2. Stated willingness to comply with all study procedures and availability to attend all required visits for the duration of the study.\n3. Age 21- 75\n4. Unilateral total knee arthroplasty at Colorado Joint Replacement\n5. All individuals will be screened for drug use (opioid use, illicit drug use) at their preoperative appointment\n6. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.\n\nExclusion Criteria:\n\n1. Narcotic use in the past 6 weeks\n2. Current or previous history of drug and alcohol abuse\n3. Tobacco use in the previous 90 days\n4. Treatment with another investigational drug\n5. Patients that cannot receive spinal anesthesia\n6. Patients that cannot receive the standardized multimodal pain medications (i.e. Tylenol, gabapentin and meloxicam)'\n7. Patients that are not able to go home after leaving the hospital and require a short-term rehabilitation facility\n8. Obstructive sleep apnea\n9. Morbid obesity (BMI \\>40)\n10. Patients with liver disease.\n11. Significant kidney disease - stage 3 CKD or greater\n12. Pregnant or nursing females\n13. Baseline QTc \\>480\n14. severe COPD (GOLD 3 or 4)\n15. home oxygen requirement","ALL","21 Years","75 Years",{"count":20,"type":21},192,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this study is to determine whether one dose of IV methadone given right before surgery will help patients' pain management after a total knee replacement and reduce the amount of pain medications taken in the weeks after surgery.",[27],"Total Knee Arthroplasty",[29,30,31],"pain management","TKA","methadone","RECRUITING","2026-06-16",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":36},"2026-06-01",{"date":40,"type":21},"2028-06",{"name":42,"class":43},"AdventHealth","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":44},"100559288","a-prospective-single-center-investigation-of-the-da-vinci-sp-surgical-system-in-hepatopancreaticobiliary-and-foregut-operations-for-benign-and-malignant-disease-100559288","NCT06562179","A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease","A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease.","Inclusion Criteria\n\nCholecystectomy Stage 1 - Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years of age\n* Either male or female\n* BMI ≤ 26 kg\u002Fm2\n* ASA ≤ 3\n* Diagnosed with benign disease\n\nFundoplication Stage 1- Inclusion Criteria:\n\n* Patients diagnosed with GERD and\u002For hiatal hernia\n* Patients between the ages of 18 and 80 years of age\n* Either men or women\n* BMI ≤ 26 kg\u002Fm2\n* ASA ≤ 3\n\nGastrectomy Stage 2- Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years of age\n* Either men or women\n* BMI ≤ 26 kg\u002Fm2\n* ASA ≤ 3\n* Diagnosed with benign or relatively early malignant disease of the stomach\n* AJCC 8th edition T0 or T1 tumor pathology\n* AJCC 8th edition T2, T3, tumor pathology (following neoadjuvant therapy if necessary) at the discretion of the investigator\n* Free of metastatic disease\n\nDistal Pancreatectomy Stage 2- Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years of age\n* Either men or women\n* BMI ≤ 26 kg\u002Fm2\n* ASA ≤ 3\n* Diagnosed with benign or malignant disease of the pancreas\n* No vascular involvement\n* Free of metastatic disease\n\nPancreaticoduodenectomy Stage 3- Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years of age\n* Either men or women\n* BMI ≤ 26 kg\u002Fm2\n* ASA ≤ 3\n* Diagnosed with benign or malignant disease of the pancreas\n* Diagnosed with benign or malignant distal bile duct disease\n* No vasculature involvement (i.e., no T4 disease, pancreatic or Stage 4a or b disease, or distal bile duct Stage 3b or 4 disease)\n* Free of metastatic disease\n\nEsophagectomy Stage 3- Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years of age\n* Either men or women\n* BMI ≤ 26 kg\u002Fm2\n* ASA ≤ 3\n* Diagnosed with benign or malignant disease of the esophagus\n* AJCC 8th edition T0, T1a, T1b, T2 (without other indications for neoadjuvant therapy) tumor pathology\n* AJCC 8th edition some T2, T3, or T4a, (following neoadjuvant therapy) at the discretion of the investigator\n* Free of metastatic disease\n\nHepatectomy Stage 4- Inclusion Criteria:\n\n* Patients between the ages of 18 and 80 years of age\n* Either men or women\n* BMI ≤ 26 kg\u002Fm2\n* ASA ≤ 3\n* Diagnosed with benign or malignant disease of the liver or bile duct\n* Free of metastatic disease, not including metastatic disease to the liver (e.g., colorectal liver metastases)\n\nExclusion Criteria\n\nCholecystectomy Stage 1- Exclusion Criteria:\n\n* Subject requiring an emergent operation\n* Pregnancy or nursing\n* BMI \\> 26 kg\u002Fm2\n* Previous abdominal surgery\n* Subjects with malignant disease\n* Inability to provide informed consent\n* Contraindicated for general anesthesia or minimally invasive surgery\n\nFundoplication Stage 1- Exclusion Criteria:\n\n* Subject requiring an emergent operation\n* Pregnancy or nursing\n* BMI \\> 26 kg\u002Fm2\n* Previous abdominal surgery\n* Inability to provide informed consent\n* Contraindicated for general anesthesia or minimally invasive surgery\n\nGastrectomy Stage 2- Exclusion Criteria:\n\n* Subject requiring an emergency operation\n* Pregnancy or nursing\n* BMI \\> 26 kg\u002Fm2\n* Previous abdominal surgery\n* Inability to provide informed consent\n* Contraindicated for general anesthesia or minimally invasive surgery\n* AJCC 8th edition T2, T3, T4a, T4b tumor pathology (without neoadjuvant therapy unless contraindicated)\n* Clinical or radiological evidence of distant metastatic disease\n\nDistal Pancreatectomy Stage 2- Exclusion Criteria:\n\n* Subject requiring an emergent operation\n* Pregnancy or nursing\n* BMI \\> 26 kg\u002Fm2\n* Previous abdominal surgery\n* Inability to provide informed consent\n* Contraindicated for general anesthesia or minimally invasive surgery\n* Tumor involvement with surrounding vasculature (e.g., common hepatic artery, superior mesenteric artery, superior mesenteric vein, portal vein)\n* Clinical or radiological evidence of metastatic disease\n\nPancreaticoduodenectomy Stage 3- Exclusion Criteria:\n\n* Subject requiring an emergent operation\n* Pregnancy or nursing\n* BMI \\> 26 kg\u002Fm2\n* Previous abdominal surgery\n* Inability to provide informed consent\n* Contraindicated for general anesthesia or minimally invasive surgery\n* Tumor involvement with surrounding vasculature (e.g., T4a for pancreatic disease: common hepatic artery, superior mesenteric artery, superior mesenteric vein, portal vein)\n* Tumor involvement with surrounding vasculature (e.g., T3b for bile duct disease: common hepatic artery, superior mesenteric artery, superior mesenteric vein, portal vein)\n* Clinical or radiological evidence of metastatic disease\n\nEsophagectomy Stage 3- Exclusion Criteria:\n\n* Subject requiring an emergency operation\n* Pregnancy or nursing\n* BMI \\> 26 kg\u002Fm2\n* Previous abdominal surgery\n* Inability to provide informed consent\n* Contraindicated for general anesthesia or minimally invasive surgery\n* AJCC 8th edition T2 (in some circumstances), T3, and T4a tumor pathology (without neoadjuvant therapy)\n* Clinical or radiological evidence of distant metastatic disease\n\nHepatectomy Stage 4- Exclusion Criteria:\n\n* Subject requiring an emergency operation\n* Pregnancy or nursing\n* BMI \\> 26 kg\u002Fm2\n* Previous abdominal surgery\n* Inability to provide informed consent\n* Contraindicated for general anesthesia or minimally invasive surgery\n* Perihilar cholangiocarcinoma (i.e., Klatskin tumor)\n* Involvement of major vasculature (ex: portal vein, hepatic artery, or inferior vena cava)\n* Clinical or radiological evidence of metastatic disease","18 Years","80 Years",{"count":55,"type":21},35,[57],"NA","The purpose of this study is to collect data to evaluate safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in hepatopancreatic biliary (HPB) and Foregut operations. HPB and Foregut operations of this study consist of cholecystectomy, fundoplication, gastrectomy, distal pancreatectomy, pancreaticoduodenectomy, esophagectomy, and hepatectomy.",[60],"Hepatopancreaticobiliary and Foregut Operations",[62,63,64,65,66,67],"SP DaVinci","Gallbladder removal","Esophageal procedures","Gastric resections","Pancreas procedures","Liver procedures","2026-06-09",{"date":70,"type":36},"2026-06-11",{"date":72,"type":36},"2024-05-14",{"date":74,"type":21},"2030-06",{"name":42,"class":43},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":44},"100632129","the-treatment-of-painful-diabetic-neuropathy-with-diet-100632129","NCT07509671","The Treatment of Painful Diabetic Neuropathy With Diet","The Treatment of Painful Diabetic Neuropathy With Diet, a Randomized-controlled Trial","Inclusion Criteria:\n\n* Definitive diagnosis of type II diabetes mellitus (HgA1c ≥ 6.5) or pre-diabetes (HgA1c 5.7-6.4)\n* objective documentation of peripheral neuropathy on EMG\u002FNCS testing defined as a sural-to-radial amplitude ratio of 0.21 or less\n* presence of painful neuropathy in addition to decreased sensation\n* with pain rated ≥4\u002F10 on a 0-10 numerical rating scale (NRS)\n* age 18 years or older\n* ability to provide informed consent\n* ability to attend follow-up visits.\n\nExclusion Criteria:\n\n* Potential causes of neuropathy other than type II diabetes mellitus (as listed below)\n* type I diabetes\n* vitamin B12 deficiency\n* folate deficiency\n* thyroid dysfunction,\n* other nutritional deficiencies\n* autoimmune disorders\n* inflammatory disorders\n* HIV\u002FAIDS\n* exposure to metals or toxins\n* multiple myeloma,\n* moderate to severe lumbar stenosis with neurogenic claudication",{"count":84,"type":21},40,[57],"The purpose of this clinical trial is to determine whether targeted nutritional changes can improve symptoms of painful diabetic neuropathy. Impaired blood flow to peripheral nerves-resulting in reduced oxygen delivery and subsequent nerve injury-is a well-established contributor to neuropathy. Prior studies have shown that a whole-food, plant-based diet without added oils can improve or even reverse arterial disease, suggesting a potential mechanism for enhancing nerve perfusion and function.\n\nThis study is a randomized controlled trial comparing a whole-food, plant-based diet with standard pharmacologic management for painful diabetic neuropathy.",[88,89,90],"Painful Diabetic Neuropathy (PDN)","Peripheral Neuropathy With Type 2 Diabetes","Vegan Diet",[92,93,94,95,96,97],"painful","diabetic","neuropathy","peripheral neuropathy","diabetes","diabetes type 2","2026-04-27",{"date":100,"type":36},"2026-04-30",{"date":102,"type":36},"2024-04-23",{"date":104,"type":21},"2028-02-28",{"name":42,"class":43},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100525921","comparing-endoscopic-ultrasound-vs-surgical-gastrojejunostomy-for-management-of-goo-100525921","NCT06128018","Comparing Endoscopic Ultrasound vs Surgical Gastrojejunostomy for Management of GOO.","A Randomized Trial Comparing Endoscopic UltraSound-guided GasTrojejunostomy (EUS-GJ) and Surgical GastrojejunOstomy (S-GJ) for the Management of Malignant gastRic outlEt Obstruction","RESTORE","Inclusion Criteria:\n\n1. ≥ 18 years of age.\n2. Radiographic OR Endoscopic evidence of an obstructing neoplasm in the distal stomach or duodenum.\n3. GOOSS of 0 or 1\n4. BOTH surgical and endoscopic GJ are technically and clinically feasible\n5. Can understand and is willing to sign informed consent form prior to the initiation of any study procedures (or when applicable the subject's LAR).\n\nExclusion Criteria:\n\n1. \\\u003C 18 years of age\n2. ECOG \\>2\n3. Expected survival (determined by the treating oncologist) is less than 2 months.\n4. Candidates for potential resection of the cancer and obstructed anatomical area (this includes patients with borderline resectable pancreatic cancer)\n5. Peritoneal carcinomatosis with associated bowel obstruction on imaging or during laparoscopy\n6. Large volume ascites (patients with moderate volume ascites may undergo IR guided drainage prior to randomization)\n7. Anatomical factors that technically hinder EUS-GJ OR Surgical-GJ (diffuse tumor involvement in path of LAMS or surgery, surgically altered anatomy that interferes with the ability to perform an anastomosis etc)\n8. Pregnancy",{"count":115,"type":21},70,[57],"The goal of this interventional study is to learn about the outcomes between two options for the management of malignant gastric outlet obstruction.",[119],"Malignant Gastric Outlet Obstruction","2026-04-23",{"date":98,"type":36},{"date":123,"type":36},"2023-11-01",{"date":125,"type":21},"2027-03-08",{"name":42,"class":43},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":44},"100629242","professional-readiness-through-emotional-preparedness-prep-100629242","NCT07472127","Professional Readiness Through Emotional Preparedness (PREP)","Professional Readiness Through Emotional Preparedness (PREP): A Quasi-experimental Study of a Workshop Series for Newly Licensed Nurses in Residency Programs","PREP","Inclusion Criteria:\n\n* Nurse resident employed by AdventHealth working in acute care\u002Fhospital setting\n* Able to speak, read, and understand English\n* Able to provide informed consent\n* Willing and able to comply with study procedures and requirements for duration of study\n\nExclusion Criteria:\n\n* Not in a current RN residency program\n* Unwilling or unable to comply with all study procedures and requirements for the duration of the study",true,{"count":137,"type":21},212,[57],"The purpose of this study is to examine the impact of the PREP program on participants' psychological and occupational well-being, and work readiness",[141],"Burnout","NOT_YET_RECRUITING","2026-03-11",{"date":145,"type":36},"2026-03-16",{"date":147,"type":21},"2026-03-03",{"date":149,"type":21},"2028-07-30",{"name":42,"class":43},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":158,"minAge":52,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":44},"100602302","a-prospective-study-of-a-lifestyle-medicine-survivorship-program-for-patients-with-gynecologic-cancer-100602302","NCT07121738","A Prospective Study of a Lifestyle Medicine Survivorship Program for Patients With Gynecologic Cancer","HEAL-GYN","Inclusion Criteria:\n\n* Adult 18 years old or over\n* Diagnosis of gynecologic cancer\n* Current patient in the Central Florida area\n* Completing or have completed chemotherapy treatment within approximately the past 3 months before starting the program\n* Able to speak, read, and understand the English language.\n\nExclusion Criteria:\n\n* Not willing or able to provide informed consent\n* Not willing or able to comply with all study procedures and requirement for the duration of the study","FEMALE",{"count":160,"type":21},64,[57],"This study will examine the effects of an 8-week intervention called the Healthy Eating Active Lifestyle (HEAL)-GYN program on participants' 1) self-efficacy 2) lifestyle factors, including physical activity and diet, as well as mental health and overall well-being, and 3) biometrics and biomarkers.",[164],"Gynecologic Cancers","2026-03-02",{"date":147,"type":36},{"date":168,"type":36},"2025-12-08",{"date":170,"type":21},"2026-08-31",{"name":42,"class":43},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":44},"100615854","a-pilot-study-of-rise-for-nurse-managers-retreat-100615854","NCT07298018","A Pilot Study of RISE for Nurse Managers Retreat","Inclusion Criteria:\n\n* an employed AdventHealth Nurse Manager\n* a \"moderate\" or \"high\" score in burnout equal to ≥17 in the Emotional Exhaustion Domain and\u002For ≥7 in the Depersonalization Domain on the MBI\n\nExclusion Criteria:\n\n* a direct care RN, Nurse Director, Educator, and Executive\n* a \"low\" score in burnout equal to \\\u003C17 in the Emotional Exhaustion domain and\u002For \\\u003C7 in the Depersonalization domain on the MBI",{"count":179,"type":21},16,[57],"The purpose of this study is to determine the feasibility and acceptability of the RISE for Nurse Managers retreat and its impact on occupational and psychological well-being indicators",[141,183,184],"Secondary Traumatic Stress","Perceived Stress","2026-02-17",{"date":187,"type":36},"2026-02-19",{"date":189,"type":21},"2026-02-01",{"date":191,"type":21},"2026-12-16",{"name":42,"class":43},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":200,"minAge":52,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":44},"100564618","phase-1-neoadjuvant-darolutamide-and-relugolix-combination-preceding-radical-prostatectomy-for-prostate-cancer-100564618","NCT06631521","Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for High Risk Localized and Locally Advanced Prostate Cancer: A Phase I\u002FIb Trial","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed adenocarcinoma of the prostate\n2. ECOG performance status 0-1\n3. Ability to swallow oral medications and comply with study procedures and requirements.\n4. Males ≥18 years\n5. Participants must have adequate organ and marrow function as below:\n\n   1. Absolute neutrophil count (ANC) ≥1,500\u002Fmm3 or ≥1.5 x 109\u002FL;\n   2. Platelets ≥100,000\u002Fmm3 or ≥100 x 109\u002FL;\n   3. Hemoglobin ≥8 g\u002FdL (may have been transfused).\n   4. Estimated creatinine clearance ≥30 mL\u002Fmin as calculated using the Cockcroft-Gault equation.\n   5. Total serum bilirubin \\<1.5 x upper limit of normal (ULN), less than 2.0 x ULN if suspected Gilbert's syndrome;\n   6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 2.5 x ULN.\n6. Must be a candidate for RP\n7. Clinical stage cT2-4, N0-1\n8. Mandatory to identify tumor availability (≥10 FFPE slides, 5 µM thickness \\& 1 stained H\\&E slide OR tumor block)\n9. High-risk PCa defined as one of the following-\n\n   * Gleason score (GS) ≥ 4 + 3 with ≥ 6 positive systematic biopsies (SB)\n   * GS ≥ 4 + 3 with ≥ 3 SB and prostate-specific antigen (PSA) ≥ 20 ng\u002FmL\n   * GS ≥ 9 in ≥ 1 SB or targeted biopsies (TB) -≥ 2 SB or TB with continuous GS ≥ 8, each with ≥ 80% involvement.\n\nExclusion Criteria:\n\n1. Histologic variants including neuroendocrine differentiation, small cell, sarcomatoid, ductal adenocarcinoma, squamous or transitional cell carcinoma) comprising more than 50% of the sample as determined by pathology review\n2. Participants who have had chemotherapy or radiotherapy within 4 weeks prior to planned cycle 1 day 1 of study treatment.\n3. Participants who have received anti-neoplastic intervention or experimental antineoplastic therapy within 14 days of planned cycle 1 day 1 of study therapy.\n4. Participants who are receiving any other investigational agents.\n5. Participants who have previously received darolutamide, relugolix, LHRH agonist\u002Fantagonist or another novel androgen blocking therapy (abiraterone, apalutamide, enzalutamide) within 1 year are excluded (prior bicalutamide that was discontinued ≥14 days prior to planned cycle 1 day 1 is allowed).\n6. Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e. have residual toxicities ≥Grade 2) with the exception of alopecia.\n7. Any of the following within 6 months before planned cycle 1 day 1 of study therapy:\n\n   * Stroke\n   * Myocardial infarction\n   * Severe\u002Funstable angina pectoris\n   * Coronary\u002Fperipheral artery bypass graft\n   * Congestive heart failure New York Heart Association (NYHA) Class III or IV.\n8. Known or suspected contraindications, hypersensitivity or allergy to darolutamide or relugolix or to any of their excipients.\n9. Participants with hepatitis C, hepatitis B or human immunodeficiency (HIV) who are on anti-viral therapy that has the potential to interact with darolutamide or relugolix.\n10. Participants treated with drugs known to be strong inhibitors and\u002For inducers of cytochrome P450 3A4 (CYP3A4) and the treatment cannot be discontinued or switched to a different medication at least 5 half-lives prior to starting study drug.\n11. NOTE: precaution is warranted with concomitant use of agents with a narrow therapeutic index that are substrates of P-gp, BCRP and OCT1.\n12. The participant has serious and\u002For uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \\[e.g. estimated creatinine clearance less than 30ml\u002Fmin\\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).\n13. Concurrent active malignancy whose natural history or treatment has the potential to interfere with safety or efficacy assessment of the investigational regimen. Patients with non-melanomatous skin cancer, superficial bladder cancer, cancer not needing active therapy for at least 2 years, cancer for which the treating investigator deems the subject to be in remission, or any prior malignancy that was treated with curative intent (no evidence of disease for at least 3 years) are permitted to enroll.","MALE",{"count":202,"type":21},30,[204],"PHASE1","The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in adult males.",[207,208,209],"Prostate CA","Prostate Cancer (Adenocarcinoma)","Prostate Cancer Surgery",[211,212,213,214,215,216,217,218,219,220],"Prostate Cancer","High-Risk Prostate Cancer","Neoadjuvant Therapy","Radical Prostatectomy","Darolutamide","Relugolix","Androgen Receptor Antagonists","Gonadotropin-Releasing Hormone Antagonists","Clinical Trial Phase I\u002FIb","PSA Response","2026-02-03",{"date":223,"type":36},"2026-02-05",{"date":225,"type":36},"2024-10-22",{"date":227,"type":21},"2026-06",{"name":42,"class":43},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":236,"targetDuration":238,"studyType":239,"phases":4,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":44},"100508791","prospective-evaluation-of-the-clinical-utility-of-peroral-endoscopic-myotomy-for-gastrointestinal-motility-disorders-100508791","NCT05905016","Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy for Gastrointestinal Motility Disorders","POEM","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Scheduled to undergo POEM\n\nExclusion Criteria:\n\n1. Any contraindication to performing endoscopy.\n2. Participation in another research protocol that could interfere or influence the outcomes measures of the present study.",{"count":237,"type":21},600,"12 Months","OBSERVATIONAL","This is prospective data recording study. All patients will receive standard medical care and no experimental interventions will be performed.",[242,243,244,245,246],"Achalasia","Esophageal Spasm, Diffuse","Gastroparesis","Swallowing Disorder","Zenker Diverticulum","2026-01-29",{"date":249,"type":36},"2026-02-02",{"date":251,"type":36},"2021-10-01",{"date":253,"type":21},"2027-04",{"name":42,"class":43},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":263,"targetDuration":238,"studyType":239,"phases":4,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":44},"100475214","endoscopic-submucosal-dissection-esd-100475214","NCT05468008","Endoscopic Submucosal Dissection (ESD)","Prospective Evaluation of the Clinical Utility of Endoscopic Submucosal Dissection (ESD) in Western Population","ESD","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled to undergo ESD\n\nExclusion Criteria:\n\n* Any contraindication to performing endoscopy\n* Participation in another research protocol that could interfere or influence the outcomes measures of the present study.",{"count":264,"type":21},1000,"This registry is to evaluate the procedural and clinical outcomes in patients undergoing endoscopic submucosal dissection. All patients will receive standard of medical care and no experimental interventions will be performed.",[267,268,269],"Esophageal Lesion","Barrett Esophagus","Gastrointestinal Lesions",{"date":249,"type":36},{"date":272,"type":36},"2022-02-04",{"date":274,"type":21},"2027-12",{"name":42,"class":43},{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":4},"100620419","phase-3-evaluating-suzetrigine-for-pain-control-following-tka-100620419","NCT07357376","Evaluating Suzetrigine for Pain Control Following TKA","Evaluating a Non-Opioid Analgesic Strategy for Enhanced Recovery After Total Knee Arthroplasty: A Randomized Controlled Trial of Suzetrigine","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for elective, unilateral primary total knee arthroplasty\n* Able to tolerate oral medications after surgery\n\nExclusion Criteria:\n\n* Revision or bilateral total knee arthroplasty\n* American Society of Anesthesiologists (ASA) physical status classification greater than 3\n* Severe renal impairment (estimated glomerular filtration rate less than 15 mL\u002Fmin\u002F1.73 m²)\n* Severe hepatic impairment (Child-Pugh Class C)\n* Chronic opioid use of 30 morphine milligram equivalents per day or greater for more than 3 months\n* Pregnancy or breastfeeding\n* Seizure disorder or known hypersensitivity to suzetrigine\n* Use of medications contraindicated with CYP3A metabolism\n* Active gastrointestinal ulcer or bleeding",{"count":284,"type":21},210,[286],"PHASE3","The goal of this clinical trial is to learn if a non-opioid pain medicine called suzetrigine works to treat pain after total knee replacement surgery in adults. It will also learn about the safety of suzetrigine. The main questions it aims to answer are:\n\nDoes suzetrigine lower the amount of opioid pain medicine participants use after surgery?\n\nDoes suzetrigine have any effect on postoperative patient-reported outcomes, including pain scores, range of motion, length of stay, and KOOS\u002FPROMIS surveys?\n\nResearchers will compare suzetrigine to a placebo to see if suzetrigine works to treat pain after total knee replacement surgery.\n\nParticipants will:\n\nTake suzetrigine or a placebo by mouth for 14 days after surgery\n\nReceive standard pain care, including opioid pain medicine only if needed\n\nReport their pain levels using short daily surveys\n\nAttend routine follow-up visits after surgery",[289],"Postoperative Pain Following Knee Arthroplasty",[27,291,292,293,294,295],"Postoperative Pain","Journavx","Suzetrigine","Opioid","Enhanced Recovery","2026-01-20",{"date":298,"type":36},"2026-01-22",{"date":300,"type":21},"2026-03-01",{"date":302,"type":21},"2026-08-01",{"name":42,"class":43},{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":135,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":321,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":4},"100620571","surgical-care-and-recovery-with-laser-evaluation-trial-scarlet-100620571","NCT07359352","Surgical Care And Recovery With Laser Evaluation Trial (SCARLET)","SCARLET","Inclusion Criteria:\n\nAdults aged 18 years or older.\n\nScheduled to undergo one or more of the following major body-contouring procedures during the study period:\n\nBrachioplasty (arm lift)\n\nChest or breast contouring surgery\n\nAbdominoplasty or panniculectomy\n\nButtock lift or lower body lift\n\nThighplasty (thigh lift)\n\nAble and willing to provide written informed consent.\n\nAble to read and write in English (required for completion of validated questionnaires).\n\nWilling and able to comply with scheduled follow-up visits, questionnaires, and study procedures for up to 12 months post-surgery.\n\nExclusion Criteria:\n\nInability or unwillingness to provide informed consent.\n\nInability to comply with study visits or procedures.\n\nNon-English speakers, as the validated SCAR-Q and POSAS instruments are not currently available in equivalent translations.\n\nCurrent use of nicotine or nicotine-containing products, including cigarettes, vaping, chewing tobacco, or nicotine replacement therapy, due to the known adverse effects of nicotine on wound healing and scar formation.\n\nAny medical condition, treatment, or circumstance that, in the opinion of the Investigator, may increase participant risk, compromise safety, or interfere with study participation or data integrity.\n\nPregnant or breastfeeding women (laser\u002FBBL therapy contraindicated in pregnancy).\n\nHistory of abnormal scar formation such as keloids or hypertrophic scarring (if deemed clinically significant by the investigator).\n\nRecent energy-based treatment (laser, IPL, or BBL) to the surgical site within the previous 3 months.",{"count":312,"type":21},150,[57],"The Surgical Care and Recovery with Laser Evaluation Trial (S.C.A.R.L.E.T.) is a prospective, single-center clinical study conducted at AdventHealth Medical Group Plastic and Reconstructive Surgery at Innovation Tower. The study evaluates whether early adjuvant ProFractional laser and\u002For Broadband Light (BBL) therapy improves the appearance, texture, and patient-reported outcomes of surgical scars following major body-contouring procedures. Participants undergoing qualifying surgeries will be grouped as either cosmetic (receiving three laser\u002FBBL sessions) or non-cosmetic (receiving standard care only). Scar outcomes will be assessed using validated instruments-SCAR-Q and Patient and Observer Scar Assessment Scale (POSAS)-along with standardized photographic analysis at serial follow-ups through six months postoperatively.",[316,317,318,319,320],"Post-surgical Scars","Hypertrophic Scars","Scar Appearance Dissatisfaction","Aesthetic Surgical Outcomes","Wound Healing After Body-contouring Surgery",[322,323,324,325,326,327,328,329,330],"Surgical scar","Postoperative scar","Hypertrophic scar","Body-contouring surgery","Abdominoplasty scar","Brachioplasty scar","Thighplasty scar","Scar revision","Laser-assisted scar remodeling","2026-01-14",{"date":298,"type":36},{"date":334,"type":21},"2026-04-01",{"date":336,"type":21},"2027-10-01",{"name":42,"class":43},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":347,"conditions":348,"keywords":356,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":44},"100599211","comparative-analysis-of-hearing-outcomes-robotic-vs-manual-insertion-of-cochlear-implants-100599211","NCT07081542","Comparative Analysis of Hearing Outcomes: Robotic vs. Manual Insertion of Cochlear Implants","Inclusion Criteria:\n\n* Cochlear implant candidates \\>18 years of age\n* LFPTA (125Hz, 250Hz, 500Hz) \\\u003C80dB\n\nExclusion Criteria:\n\n* Pediatric patients (below the age of 18)\n* LFPTA (125Hz, 250Hz, 500Hz) \\>80dB\n* Revision cases\n* Severe comorbidities that contraindicate surgery.\n* Preexisting cochlear anomalies.\n* Do not speak English or Spanish",{"count":345,"type":21},32,[57],"This research study is evaluating two different methods of cochlear implant (CI) insertion - robotic-assisted insertion and manual insertion - to better understand how they affect hearing outcomes. Participants in this study will be randomly assigned to receive their cochlear implant using one of these two techniques. Both methods are performed in a standard operating room by qualified surgeons, and both are considered safe and approved for use.\n\nThe main goal is to compare how well participants hear one year after surgery based on the insertion method used. The study will also look at things like surgical time, inner ear health, and how the hearing nerve responds. All participants will receive the same type of cochlear implant device and follow-up care.\n\nThis study may help guide future surgical techniques and improve outcomes for individuals receiving cochlear implants.",[349,350,351,352,353,354,355],"Sensorineural Hearing Loss","Bilateral Hearing Loss","Cochlear Implantation","Hearing Disorders","Hearing Disorders and Deafness","Inner Ear Disorders","Hearing Impairment",[357,358,359,360,361,362,363,364],"Cochlear Implant","Robotic Cochlear Implant Insertion","Hearing Performance","Speech Perception","Electrocochleography","Hearing Rehabilitation","Postoperative Hearing Outcomes","Minimally Invasive ENT Surgery","2025-12-30",{"date":367,"type":36},"2026-01-02",{"date":369,"type":21},"2026-01-01",{"date":371,"type":21},"2027-01-31",{"name":42,"class":43},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":239,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":44},"100552673","evaluating-adenoma-recurrence-after-endoscopic-mucosal-resection-with-margin-marking-or-post-treatment-with-snare-tip-soft-coagulation-100552673","NCT06476145","Evaluating Adenoma Recurrence After Endoscopic Mucosal Resection With Margin Marking or Post Treatment With Snare Tip Soft Coagulation","Prospective Randomized Controlled Trial Evaluating Adenoma Recurrence After Endoscopic Mucosal Resection With Margin Marking or Post Treatment With Snare Tip Soft Coagulation","ERADICATE","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Ability to provide informed consent\n3. Patient scheduled to undergo colonoscopy for the evaluation and removal of colon polyps\n4. Non-pedunculated polyps ≥ 20 mm size\n\nExclusion Criteria:\n\n1. Pedunculated polyps\n2. Inflammatory bowel disease\n3. Inability to provide informed consent\n4. Lesions \\\u003C 20 mm in size (largest dimension)\n5. Lesion involves the lips of the ileocecal valve, is located at the appendiceal orifice and\u002For is fully circumferential.\n6. Any standard contraindication, including pregnancy, to anesthesia and\u002For colonoscopy",{"count":382,"type":21},342,"Non-inferiority trial comparing the recurrence rate of adenomas in non-pedunculated colonic lesions following endoscopic mucosal resection with margin marking (EMR-MM) and endoscopic mucosal resection with thermal margin ablation (EMR-STSC)",[385],"Adenoma Colon Polyp",{"date":387,"type":36},"2026-01-05",{"date":389,"type":36},"2023-12-08",{"date":391,"type":21},"2027-01-08",{"name":42,"class":43},{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":135,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":399,"targetDuration":238,"studyType":239,"phases":4,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":410,"locationsCount":44},"100610713","building-on-trust-navigating-preventive-lung-breast-and-prostate-cancer-screenings-at-community-resource-spots-100610713","NCT07231159","Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots","Inclusion Criteria:\n\n1. Adult aged 18 or older\n2. Seeking care at a CRS or emergency department\n3. Meets criteria for lung, breast, and\u002For prostate cancer screening, as outlined below:\n\n   1. Lung cancer: Adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years\n   2. Breast cancer: Women aged 40 to 74 years\n   3. Prostate cancer: Men aged 55 to 69 years\n4. Receives a positive screening result for lung, breast, and\u002For prostate cancer at a study site\n\nExclusion Criteria:\n\n1. Displays behavior disruptive to other patients or staff\n2. Refusal to accept screening for breast, lung, and\u002For prostate cancers",{"count":400,"type":21},200,"To evaluate a community-based outreach initiative for screening, diagnosis, and treatment of breast, lung, and prostate cancers in underserved adults using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) implementation science framework.",[403,404,211],"Breast Cancer","Lung Cancer (Diagnosis)","2025-11-14",{"date":407,"type":36},"2025-11-17",{"date":407,"type":21},{"date":170,"type":21},{"name":42,"class":43},{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":417,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":44},"100506707","targeting-network-dysfunction-in-apathy-of-late-life-depression-using-digital-therapeutics-100506707","NCT05877885","Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics","Inclusion Criteria:\n\n1. Age 60+ years\n2. Diagnosis of unipolar major depressive disorder without psychotic features, as assessed by the Mini International Neuropsychiatric Interview\n3. Montgomery-Åsberg Depression Rating Scale (MADRS) score \\> or = 16.\n4. Clinically significant apathy, determined by the Clinician-rated Apathy Evaluation Scale (C-AES \\> or = to 37)\n5. Off antidepressants or on a stable dose of an antidepressant for 8 weeks and do not intend to change the dose in the next 5 weeks.\n6. On a stable dose of other psychotropic medications, deemed by the investigator to be associated with brain networks of interest, for at least 8 weeks.\n7. Capacity to provide written consent for research assessment and treatment\n8. Ability to follow written and verbal instructions (English) as assessed by the PI and\u002For study staff.\n9. Total score of \\> 29 on the Telephone Interview for Cognitive Status (TICS)\n10. Eligible to undergo MRI\n11. Access to a computer or tablet with Wifi capabilities\n12. Able to comply with all testing and study requirements and willingness to participate in the full study duration.\n\nExclusion Criteria:\n\n1. History or presence of psychiatric diagnoses other than major depressive disorder without psychotic features, persistent depressive disorder, generalized anxiety disorder, social anxiety disorder, or specific phobia\n2. Use of cholinesterase inhibitors or psychoactive drugs other than antidepressants or benzodiazepines, including antipsychotics, that in the opinion of the Investigator may confound study data\u002Fassessments.\n3. Presence or history of significant neurologic or neurodegenerative disorder (e.g., Alzheimer's disease and other dementias, amnestic Mild Cognitive Impairment, history of stroke, Multiple Sclerosis, Parkinson's disease, epilepsy).\n4. Any other acute medical condition (e.g., cardiac, renal, or respiratory failure; severe chronic obstructive pulmonary disease; metastatic cancer; or debilitated states or less common medical illnesses) that may influence brain systems of interest or interfere with participation or interpretation of the study results.\n5. Participant is currently considered at risk for attempting suicide by the Investigator, has made a suicide attempt within the past year, or is currently demonstrating active suicidal ideation or self-injurious behavior.\n6. Electroconvulsive therapy within the past 12 months\n7. Recent history (within 6 months prior to screening\u002Fbaseline) of Substance Use Disorder.\n8. Participant is currently enrolled in ongoing concurrent cognitive rehabilitation (note that if a subject is enrolled in psychotherapy, this will not be grounds for exclusion)\n9. Claustrophobia\n10. Color Blindness\n11. Sensory or physical impairment that would preclude cognitive testing or participation in the intervention (e.g., upper limb paralysis) as reported by the participant or observed by the Investigator.\n12. Travelling consecutively for 2+ weeks during the study period to a location that will preclude timely collection of post-treatment MRI data.\n13. Contraindications to MRI scanning including cardiac pacemaker, heart valve replacement, vascular stent, cochlear implant, any other metallic biomedical implant contraindicating to MRI.","60 Years",{"count":419,"type":21},84,[57],"The goal of this randomized controlled trial is to evaluate the potential of a customized digital cognitive training intervention to target aspects of brain function in apathy of late-life depression and reduce symptoms of apathy and related cognitive and behavioral deficits. The investigators hypothesize that 4 weeks of a customized digital cognitive training program will lead to changes in brain connectivity, apathy severity, and cognitive control performance.",[423,424],"Major Depressive Disorder","Apathy","2025-10-21",{"date":427,"type":36},"2025-10-22",{"date":429,"type":36},"2025-09-19",{"date":431,"type":21},"2028-12-01",{"name":42,"class":43},{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":239,"phases":4,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":456,"locationsCount":457},"100504755","evaluation-of-the-clinical-utility-of-endoscopic-closure-using-a-dual-action-tissue-dat-clip-100504755","NCT05852457","Evaluation of the Clinical Utility of Endoscopic Closure Using a Dual Action Tissue (DAT) Clip","Prospective Evaluation of the Clinical Utility of Endoscopic Closure Using a Dual Action Tissue (DAT) Clip","Inclusion Criteria:\n\n* Age 18 years or older.\n* Patients scheduled to undergo endoscopic procedures as part of their routine care in which endoscopic clip closure is clinically indicated:\n\nTreatment of bleeding Treatment of perforation and\u002For fistulas Tissue approximation for mucosal gaps associated with endoscopic resection (e.g., endoscopic mucosal resection, endoscopic submucosal dissection) or third space endoscopy (e.g., peroral endoscopic myotomy in the gastrointestinal tract)\n\nExclusion Criteria:\n\n* Any contraindications to performing endoscopy.\n* Participants in another research protocol that could interfere or influence the outcomes measures of the present study.",{"count":441,"type":21},250,"This study is designed as a multicenter prospective data recording study to document the performance of the DAT clip as part of standard medical care of patients. No experimental interventions will be performed.",[444,445,446,447,448,449],"GI Bleeding","Perforation Colon","Perforation Bowel","Perforation Duodenal","Perforated Bowel","Fistula","2025-10-07",{"date":452,"type":36},"2025-10-08",{"date":454,"type":36},"2022-08-31",{"date":274,"type":21},{"name":42,"class":43},2,{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":467,"briefSummary":468,"conditions":469,"keywords":474,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":482,"locationsCount":44},"100609207","the-larc-robot-simplifies-renal-access-in-percutaneous-nephrolithotomy-100609207","NCT07211555","The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy","The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy (PCNL)","Inclusion Criteria:\n\n* Kidney stones larger than 2 cm\n* Staghorn renal calculi\n* Lower pole stones less than 2 cm\n* Anatomical abnormalities that reduce the likelihood of spontaneous stone fragment passage, such as:\n* Horseshoe kidney\n* Calyceal diverticulum\n* Ectopic or dystopic kidney\n* Stones that are refractory to prior treatment (e.g., ESWL or ureteroscopy)\n* Suspected malignant tumors or masses located in the planned renal access tract\n\nExclusion Criteria:\n\n* Pregnancy\n* Active urinary tract infection (UTI) or untreated sepsis\n* Known bleeding disorders or uncorrectable coagulopathy despite medical management\n* Use of anticoagulant medications (e.g., warfarin, heparin, or DOACs) that cannot be safely discontinued\n* Allergy to contrast media that cannot be pre-medicated or managed\n* Severe cardiopulmonary comorbidities that contraindicate anesthesia or PCNL\n* Inability to provide informed consent\n* Participation in another investigational study that may interfere with study outcomes",{"count":466,"type":21},45,[57],"This study is being done to evaluate a new robotic system that helps urologists more precisely reach the kidney during surgery to remove large kidney stones. The procedure, called percutaneous nephrolithotomy (PCNL), is typically used for people who have large or difficult-to-remove kidney stones.\n\nTraditionally, many urologists rely on radiologists to place a tube into the kidney before surgery. This can cause delays, require multiple procedures, and increase costs. The robotic system being studied - called LARC - is designed to help the urologist safely and accurately guide a needle directly into the kidney during the surgery, without needing a separate procedure beforehand.\n\nThe robot uses live X-ray images to help align the instruments. Although parts of the robot have been approved by the U.S. FDA, the version used in this study is still investigational and not yet approved for this specific purpose.\n\nThe study will take place at AdventHealth Celebration and include up to 45 adult patients who are scheduled for PCNL surgery. Participants will be followed for up to 1 month after surgery, and doctors will look at outcomes such as the success of the procedure, the number of kidney stones removed, complications, time in surgery, and radiation exposure.\n\nThis research may help make kidney stone surgery safer, faster, and more effective in the future.",[470,471,472,473],"Renal Stone Disease","Kidney Calculi","Refractory Kidney Stones","Kidney Stones",[475,476],"Robotic Surgery","Minimally Invasive Surgery","2025-09-30",{"date":452,"type":36},{"date":480,"type":21},"2025-11-01",{"date":369,"type":21},{"name":42,"class":43},{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":200,"minAge":52,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":498,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":44},"100602991","exploring-the-potential-of-robotic-telesurgery-in-remote-settings-100602991","NCT07130708","Exploring the Potential of Robotic Telesurgery in Remote Settings","Advancing Humanitarian Healthcare: Exploring the Potential of Robotic Telesurgery in Remote Settings - A Multicentric Prospective Study","Inclusion Criteria:\n\n* Age 18 - 90\n* Male or female\n* Eligible participants for this telesurgery study must have a clearly defined indication for robotic urologic surgery, specifically:\n\n  * Localized Prostate Cancer (ICD-10: C61), appropriate for robotic radical prostatectomy.\n\nOR\n\n-Benign Prostate diseases appropriate for robotic simple prostatectomy (ICD-10: N40) These diagnoses are confirmed by clinical examination, imaging, and\u002For pathology prior to surgical planning. Patients with vague or unspecified urologic conditions will be excluded to ensure the safety and appropriateness of the surgical intervention.\n\n* Primary diagnosis of urinary system disease and prostate disorders (C61 and N40.1) scheduled to undergo treatment with robotic surgery. These patients don't have access to robotic surgery in their routine and the study will give them the opportunity to have advanced technology and the gold-standard treatment with experts in the field.\n* Willing to participate in the study\n* Mentally capable of comprehending the study protocol\n\nExclusion Criteria:\n\n* Patients who, based on multidisciplinary evaluation (surgical, anesthetic, and medical), are deemed not suitable for robotic surgery due to high perioperative risk. This includes but is not limited to:\n\n  * Uncontrolled cardiovascular, pulmonary, or metabolic disease.\n  * Severe anesthetic risk classified as ASA Class IV or higher.\n* Patients enrolled in another interventional research study that may interfere with surgical safety or outcomes.\n* Patients unwilling or unable to comply with the perioperative and follow-up schedule.\n* Vulnerable populations are excluded from this study, including:\n\n  * Minors (under 18 years old)\n  * Prisoners\n  * Cognitively impaired or decisional incapacitated individuals","90 Years",{"count":492,"type":21},10,[57],"This study involves a type of robotic surgery called telesurgery, where a highly trained surgeon performs the surgical procedure using a secure internet connection to operate on a patient in a different location. Urologists from The goal of this study is to find out how safe and effective telesurgery is when used in real hospitals. The study aims to understand how well Telesurgery works in different settings, what technical challenges might come up (like internet speed or delays), and how it can be used to train new surgeons.",[496,497],"Prostate Carcinoma","Prostate Disease",[499,211,500],"Robotic Prostatectomy","Telesurgery","2025-08-16",{"date":503,"type":36},"2025-08-19",{"date":505,"type":36},"2025-06-14",{"date":507,"type":21},"2033-07-30",{"name":42,"class":43},{"id":510,"slug":511,"hasResults":11,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":11,"sex":200,"minAge":52,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":517,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":44},"100563539","phase-2-pet-scan-study-to-detect-prostate-cancer-in-patients-with-early-psa-recurrence-100563539","NCT06617481","PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence","Inclusion Criteria:\n\n* History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.\n* An elevated PSA test result that is greater than or equal to 0.1 ng\u002Fml and less than 0.5\n\nExclusion Criteria:\n\n* Patients who are planned to have an x-ray contrast agent or other PET radiotracer \\& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.\n* Patients currently receiving Androgen Deprivation Therapy (ADT).",{"count":202,"type":21},[518],"PHASE2","Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.\n\nThe research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.",[521],"Prostate Cancer (Post Prostatectomy)",[523],"Rising PSA following cancer prostatectomy surgery",{"date":525,"type":36},"2024-10-24",{"date":527,"type":36},"2024-09-20",{"date":529,"type":21},"2027-10-10",{"name":42,"class":43},""]